A blinded, randomized, controlled trial of three doses of high-dose insulin in poison-induced cardiogenic shock

被引:33
|
作者
Cole, J. B. [1 ,2 ]
Stellpflug, S. J. [1 ]
Ellsworth, H. [1 ]
Anderson, C. P. [3 ]
Adams, A. B. [3 ]
Engebretsen, K. M. [1 ]
Holger, J. S. [1 ]
机构
[1] Reg Hosp, Dept Emergency Med, St Paul, MN USA
[2] Hennepin Cty Med Ctr, Dept Emergency Med, Hennepin Reg Poison Ctr, Minneapolis, MN 55415 USA
[3] HealthPartners Inst Educ & Res, Minneapolis, MN USA
关键词
High dose insulin; Cardiogenic shock; Beta blockers; BETA-BLOCKER TOXICITY; OVERDOSE; VASOPRESSIN; METOPROLOL; VERAPAMIL; GLUCAGON; CANINE; MODEL;
D O I
10.3109/15563650.2013.770152
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Background. High dose insulin (HDI) has proven superior to glucagon and catecholamines in the treatment of poison-induced cardiogenic shock (PICS) in previous animal studies. Standard recommendations for dosing of insulin vary and the optimal dose of HDI in PICS has not been established. Our hypothesis was a dose of 10 U/kg/hr of HDI would be superior to 1 U/kg/hr with cardiac output (CO) as our primary outcome measure in pigs with propranolol-induced PICS. Methods. This was a blinded, prospective, randomized trial with 4 arms consisting of 4 pigs in each arm. The arms were as follows: placebo (P), 1 U/kg/hr (HDI-1), 5 U/kg/hr (HDI-5), and 10 U/kg/hr (HDI-10). Cardiogenic shock was induced with a bolus of 0.5 mg/kg of propranolol followed by an infusion of 0.25 mg/kg/min until the point of toxicity, defined as 0.75 x (HR x MAP) was reached. At this point the propranolol infusion was decreased to 0.125 mg/kg/min and a 20 mL/kg bolus of normal saline (NS) was administered. The protocol was continued for 6 hours or until the animals died. Results. 2 pigs died in the P arm, 1 pig died each in the HDI-1 and HDI-5 arms, and all pigs lived in the HDI-10 arm. There was a statistically significant difference in dose by time interaction on CO of 1.13 L/min over the 6 hr study period (p = < 0.001). There was also a statistically significant difference in dose by time interaction on MAP, HR, and systemic vascular resistance (SVR). No statistically significant difference was found between any of the arms regarding glucose utilization. Conclusion. HDI was statistically and clinically significantly superior to placebo in this propranolol model of PICS. Furthermore a dose response over time was found where CO increased corresponding to increases in doses of HDI.
引用
收藏
页码:201 / 207
页数:7
相关论文
共 12 条
  • [1] A randomized controlled study comparing high-dose insulin to vasopressors or combination therapy in a porcine model of refractory propranolol-induced cardiogenic shock
    Katzung, Katherine G.
    Leroy, JennaM.
    Boley, Sean P.
    Stellpflug, Samuel J.
    Holger, Joel S.
    Engebretsen, Kristin M.
    CLINICAL TOXICOLOGY, 2019, 57 (11) : 1073 - 1079
  • [2] High-dose insulin: A consecutive case series in toxin-induced cardiogenic shock
    Holger, Joel S.
    Stellpflug, Samuel J.
    Cole, Jon B.
    Harris, Carson R.
    Engebretsen, Kristin M.
    CLINICAL TOXICOLOGY, 2011, 49 (07) : 653 - 658
  • [3] Premises, Premises (Poisoning-induced cardiogenic shock and High-dose Insulin)
    Seger, D.
    CLINICAL TOXICOLOGY, 2013, 51 (04) : 199 - 200
  • [4] HIGH-DOSE INSULIN FOR TOXIN INDUCED CARDIOGENIC SHOCK: EXPERIENCE AT A NEW HIGH AND OVERVIEW OF THE EVIDENCE
    Chad, Thomas
    Ulla, Marco
    Rey, Vanesa Garnelo
    Gomez, Carlos
    JOURNAL OF EMERGENCY MEDICINE, 2020, 58 (02): : 317 - 323
  • [5] Low-dose corticosteroid therapy for cardiogenic shock in adults (COCCA): study protocol for a randomized controlled trial
    Armand Mekontso Dessap
    François Bagate
    Clément Delmas
    Tristan Morichau-Beauchant
    Bernard Cholley
    Alain Cariou
    Benoit Lattuca
    Mouhamed Moussa
    Nicolas Mongardon
    Damien Fard
    Matthieu Schmidt
    Adrien Bouglé
    Mathieu Kerneis
    Emmanuel Vivier
    François Roubille
    Matthieu Duprey
    Véronique Decalf
    Thibaud Genet
    Messaouda Merzoug
    Etienne Audureau
    Pierre Squara
    Trials, 23
  • [6] Low-dose corticosteroid therapy for cardiogenic shock in adults (COCCA): study protocol for a randomized controlled trial
    Dessap, Armand Mekontso
    Bagate, Francois
    Delmas, Clement
    Morichau-Beauchant, Tristan
    Cholley, Bernard
    Cariou, Alain
    Lattuca, Benoit
    Moussa, Mouhamed
    Mongardon, Nicolas
    Fard, Damien
    Schmidt, Matthieu
    Bougle, Adrien
    Kerneis, Mathieu
    Vivier, Emmanuel
    Roubille, Francois
    Duprey, Matthieu
    Decalf, Veronique
    Genet, Thibaud
    Merzoug, Messaouda
    Audureau, Etienne
    Squara, Pierre
    TRIALS, 2022, 23 (01)
  • [7] HIGH-DOSE INSULIN AND INTRAVENOUS LIPID EMULSION THERAPY FOR CARDIOGENIC SHOCK INDUCED BY INTENTIONAL CALCIUM-CHANNEL BLOCKER AND BETA-BLOCKER OVERDOSE: A CASE SERIES
    Doepker, Bruce
    Healy, William
    Cortez, Eric
    Adkins, Eric J.
    JOURNAL OF EMERGENCY MEDICINE, 2014, 46 (04): : 486 - 490
  • [8] High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL): A Randomized Controlled Trial - Background, Aims, and Study Protocol
    Juul, Sandra E.
    Comstock, Bryan A.
    Heagerty, Patrick J.
    Mayock, Dennis E.
    Goodman, Amy M.
    Hauge, Stephanie
    Gonzalez, Fernando
    Wu, Yvonne W.
    NEONATOLOGY, 2018, 113 (04) : 331 - 338
  • [9] Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial
    Holle, Sarah Louise Duus
    Kunkel, Joakim Bo
    Hassager, Christian
    Pecini, Redi
    Wiberg, Sebastian
    Palm, Pernille
    Holmvang, Lene
    Bang, Lia Evi
    Kjaergaard, Jesper
    Thomsen, Jakob Hartvig
    Engstrom, Thomas
    Moller, Jacob Eifer
    Lonborg, Jacob Thomsen
    Soholm, Helle
    Frydland, Martin
    TRIALS, 2024, 25 (01)
  • [10] High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial
    Schreiber, Karen
    Magyari, Melinda
    Sellebjerg, Finn
    Iversen, Pernille
    Garde, Ellen
    Madsen, Camilla Gobel
    Bornsen, Lars
    Christensen, Jeppe Romme
    Ratzer, Rikke
    Siebner, Hartwig Roman
    Laursen, Bjarne
    Sorensen, Per Soelberg
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (05) : 675 - 685